Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 461

1.

Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment.

Linardou H, Kotoula V, Kouvatseas G, Mountzios G, Karavasilis V, Samantas E, Kalogera-Fountzila A, Televantou D, Papadopoulou K, Mavropoulou X, Daskalaki E, Zaramboukas T, Efstratiou I, Lampaki S, Rallis G, Res E, Syrigos KN, Kosmidis PA, Pectasides D, Fountzilas G.

Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):531-541. doi: 10.21873/cgp.20155.

PMID:
31659106
2.

Pulmonary nocardiosis associated with Cushing's disease: a case report.

Mylonas CC, Gomatou G, Asimakopoulou A, Masaoutis C, Kyriakopoulos G, Kopelia M, Syrigos K, Poulakou G.

Monaldi Arch Chest Dis. 2019 Oct 18;89(3). doi: 10.4081/monaldi.2019.1130.

3.

A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin alfa for Chemotherapy-Induced Anemia in Patients With Advanced Non-Small Cell Lung Cancer.

Gascón P, Nagarkar R, Šmakal M, Syrigos KN, Barrios CH, Sánchez JC, Zhang L, Henry DH, Gordon D, Hirsh V, Kubota K, Orlov S, Thomas G, Steinmetz T, Kang JH, Tomita DK, Fleishman AN, Park JK, De Oliveira Brandao C.

J Thorac Oncol. 2019 Oct 16. pii: S1556-0864(19)33563-4. doi: 10.1016/j.jtho.2019.10.005. [Epub ahead of print]

4.

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS.

N Engl J Med. 2019 Sep 28. doi: 10.1056/NEJMoa1910231. [Epub ahead of print]

PMID:
31562796
5.

A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.

Villaruz LC, Cobo M, Syrigos K, Mavroudis D, Zhang W, Kim JS, Socinski MA.

Lung Cancer. 2019 Oct;136:52-56. doi: 10.1016/j.lungcan.2019.08.009. Epub 2019 Aug 14.

PMID:
31445354
6.

PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study.

Reinmuth N, Bryl M, Bondarenko I, Syrigos K, Vladimirov V, Zereu M, Bair AH, Hilton F, Liau K, Kasahara K.

BioDrugs. 2019 Oct;33(5):555-570. doi: 10.1007/s40259-019-00363-4.

7.

Psychological correlates of sleep quality in lung cancer patients under chemotherapy: A single-center cross-sectional study.

Papadopoulos D, Kiagia M, Charpidou A, Gkiozos I, Syrigos K.

Psychooncology. 2019 Sep;28(9):1879-1886. doi: 10.1002/pon.5167. Epub 2019 Jul 18.

PMID:
31264308
8.

Inhibition of the Hedgehog pathway in lung cancer.

Dimou A, Bamias A, Gogas H, Syrigos K.

Lung Cancer. 2019 Jul;133:56-61. doi: 10.1016/j.lungcan.2019.05.004. Epub 2019 May 6. Review.

PMID:
31200829
9.

High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling.

Toki MI, Merritt CR, Wong PF, Smithy JW, Kluger HM, Syrigos KN, Ong GT, Warren SE, Beechem JM, Rimm DL.

Clin Cancer Res. 2019 Sep 15;25(18):5503-5512. doi: 10.1158/1078-0432.CCR-19-0104. Epub 2019 Jun 12.

PMID:
31189645
10.

Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer.

Govindan R, Senan S, Dickgreber N, Provencio M, Wu YL, Syrigos K, Parente B, Wilson M, Ziemiecki R, Chouaki N, Hossain A, San Antonio B, Winfree K, Vokes EE.

Curr Med Res Opin. 2019 Oct;35(10):1761-1767. doi: 10.1080/03007995.2019.1623185. Epub 2019 Jul 5.

PMID:
31125266
11.

Lung cancer patients' journey from first symptom to treatment: Results from a Greek registry.

Kourlaba G, Gkiozos I, Kokkotou E, Stefanou G, Papaspiliou A, Syrigos K.

Cancer Epidemiol. 2019 Jun;60:193-200. doi: 10.1016/j.canep.2019.04.014. Epub 2019 May 4.

PMID:
31063908
12.

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.

Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mejías LD, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, McEachern K, Jenkins D, Syrigos K, Politi K, Gettinger S, Rimm DL, Herbst RS, Melero I, Chen L, Schalper KA.

Clin Cancer Res. 2019 Aug 1;25(15):4663-4673. doi: 10.1158/1078-0432.CCR-18-4142. Epub 2019 May 3.

PMID:
31053602
13.

Exceptional antitumor responses beyond immune checkpoint inhibition in non-small cell lung cancer patients: insights into optimal therapy sequencing.

Charpidou A, Vathiotis I, Gkiozos I, Syrigos K.

J Thorac Dis. 2019 Mar;11(3):E25-E31. doi: 10.21037/jtd.2019.02.38. No abstract available.

14.

End-of-Life Health-Care Cost of Patients With Lung Cancer: A Retrospective Study.

Souliotis K, Kani C, Marioli A, Kamboukou A, Prinou A, Syrigos K, Markantonis S.

Health Serv Res Manag Epidemiol. 2019 Apr 10;6:2333392819841223. doi: 10.1177/2333392819841223. eCollection 2019 Jan-Dec.

15.

Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients.

Nikolaou V, Voudouri D, Tsironis G, Charpidou A, Stamoulis G, Triantafyllopoulou I, Panoutsopoulou I, Xidakis E, Bamias A, Samantas E, Aravantinos G, Gogas H, Rigopoulos D, Syrigos K, Stratigos A.

Support Care Cancer. 2019 Dec;27(12):4535-4542. doi: 10.1007/s00520-019-04751-y. Epub 2019 Mar 27.

PMID:
30919155
16.

A rare case of bone marrow BCG-itis responding to second-line anti-tuberculosis treatment.

Anagnostopoulos I, Lagou S, Papatheodoridi M, Marinos L, Karakatsanis S, Syrigos KN.

Int J Tuberc Lung Dis. 2019 Jan 1;23(1):119-120. doi: 10.5588/ijtld.18.0576. No abstract available.

PMID:
30674384
17.

PET/CT and brain MRI role in staging NSCLC: prospective assessment of the accuracy, reliability and cost-effectiveness.

Gkogkozotou VI, Gkiozos IC, Charpidou AG, Kotteas EA, Boura PG, Tsagouli SN, Syrigos KN.

Lung Cancer Manag. 2018 May 31;7(2):LMT02. doi: 10.2217/lmt-2018-0008. eCollection 2018 Jun.

18.

Crazy paving pattern as a rare radiological manifestation of peripheral T-cell lymphoma (PTCL) with lung involvement: A case report.

Gomatou G, Tzilas V, Kourti G, Lagou S, Bouros D, Syrigos K.

Respir Med Case Rep. 2018 Sep 26;25:253-256. doi: 10.1016/j.rmcr.2018.09.015. eCollection 2018.

19.

Hypoplastic thrombocytopenia and platelet transfusion: therapeutic goals.

Karakatsanis SJ, Papadatos SS, Syrigos KN.

Hosp Pract (1995). 2019 Feb;47(1):16-23. doi: 10.1080/21548331.2019.1546530. Epub 2018 Nov 14. Review.

PMID:
30409035
20.

Response to the letter to the editor: "New data for venous thromboembolism in patients with small cell lung cancer: A review".

Dimakakos E, Livanios K, Gkiozos I, Harpidou A, Ntalakou E, Kainis L, Syrigos K.

Phlebology. 2019 Mar;34(2):139-140. doi: 10.1177/0268355518812596. Epub 2018 Nov 7. No abstract available.

PMID:
30403153
21.

Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.

Toki MI, Mani N, Smithy JW, Liu Y, Altan M, Wasserman B, Tuktamyshov R, Schalper K, Syrigos KN, Rimm DL.

J Thorac Oncol. 2018 Dec;13(12):1884-1896. doi: 10.1016/j.jtho.2018.09.012. Epub 2018 Sep 26.

PMID:
30267840
22.

Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non-Small Cell Lung Cancer.

Corredor G, Wang X, Zhou Y, Lu C, Fu P, Syrigos K, Rimm DL, Yang M, Romero E, Schalper KA, Velcheti V, Madabhushi A.

Clin Cancer Res. 2019 Mar 1;25(5):1526-1534. doi: 10.1158/1078-0432.CCR-18-2013. Epub 2018 Sep 10.

PMID:
30201760
23.

Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.

Gridelli C, de Castro Carpeno J, Dingemans AC, Griesinger F, Grossi F, Langer C, Ohe Y, Syrigos K, Thatcher N, Das-Gupta A, Truman M, Donica M, Smoljanovic V, Bennouna J.

JAMA Oncol. 2018 Dec 1;4(12):e183486. doi: 10.1001/jamaoncol.2018.3486. Epub 2018 Dec 13. Erratum in: JAMA Oncol. 2018 Dec 1;4(12):1792.

24.

Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.

Syrigos K, Grapsa D, Sangare R, Evmorfiadis I, Larsen AK, Van Dreden P, Boura P, Charpidou A, Kotteas E, Sergentanis TN, Elalamy I, Falanga A, Gerotziafas GT.

Oncologist. 2018 Nov;23(11):1372-1381. doi: 10.1634/theoncologist.2017-0530. Epub 2018 Aug 13.

25.

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.

Goss GD, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC.

JAMA Oncol. 2018 Sep 1;4(9):1189-1197. doi: 10.1001/jamaoncol.2018.0775.

26.

Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping.

Papaxoinis G, Kotoula V, Giannoulatou E, Koliou GA, Karavasilis V, Lakis S, Koureas A, Bobos M, Chalaralambous E, Daskalaki E, Chatzopoulos K, Tsironis G, Pazarli E, Chrisafi S, Samantas E, Kaklamanos IG, Varthalitis I, Konstantara A, Syrigos KN, Pentheroudakis G, Pectasides D, Fountzilas G.

Med Oncol. 2018 May 31;35(7):101. doi: 10.1007/s12032-018-1160-1.

PMID:
29855806
27.

Epidemiological Characteristics, EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study.

Syrigos KN, Georgoulias V, Zarogoulidis K, Makrantonakis P, Charpidou A, Christodoulou C.

Anticancer Res. 2018 Jun;38(6):3735-3744. doi: 10.21873/anticanres.12654.

PMID:
29848736
28.

Khorana Score: Νew Predictor of Early Mortality in Patients With Lung Adenocarcinoma.

Vathiotis I, Dimakakos EP, Boura P, Ntineri A, Charpidou A, Gerotziafas G, Syrigos K.

Clin Appl Thromb Hemost. 2018 Nov;24(8):1347-1351. doi: 10.1177/1076029618777153. Epub 2018 May 27.

29.

Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors.

Gkiozos I, Kopitopoulou A, Kalkanis A, Vamvakaris IN, Judson MA, Syrigos KN.

J Thorac Oncol. 2018 Aug;13(8):1076-1082. doi: 10.1016/j.jtho.2018.04.031. Epub 2018 May 12. Review.

30.

The Autotaxin-Lysophosphatidic Acid Axis Promotes Lung Carcinogenesis.

Magkrioti C, Oikonomou N, Kaffe E, Mouratis MA, Xylourgidis N, Barbayianni I, Megadoukas P, Harokopos V, Valavanis C, Chun J, Kosma A, Stathopoulos GT, Bouros E, Bouros D, Syrigos K, Aidinis V.

Cancer Res. 2018 Jul 1;78(13):3634-3644. doi: 10.1158/0008-5472.CAN-17-3797. Epub 2018 May 3.

31.

Circulating tumor cells count as a predictor of survival in lung cancer.

Syrigos K, Fiste O, Charpidou A, Grapsa D.

Crit Rev Oncol Hematol. 2018 May;125:60-68. doi: 10.1016/j.critrevonc.2018.03.004. Epub 2018 Mar 7. Review.

PMID:
29650278
32.

Adjustable delivery of pro-angiogenic FGF-2 by alginate:collagen microspheres.

Ali Z, Islam A, Sherrell P, Le-Moine M, Lolas G, Syrigos K, Rafat M, Jensen LD.

Biol Open. 2018 Mar 12;7(3). pii: bio027060. doi: 10.1242/bio.027060.

33.

Everolimus as cancer therapy: Cardiotoxic or an unexpected antiatherogenic agent? A narrative review.

Karvelas G, Roumpi A, Komporozos C, Syrigos K.

Hellenic J Cardiol. 2018 Jul - Aug;59(4):196-200. doi: 10.1016/j.hjc.2018.01.013. Epub 2018 Mar 29. Review.

34.

Nonpharmacologic Interventions for Improving Sleep Disturbances in Patients With Lung Cancer: A Systematic Review and Meta-analysis.

Papadopoulos D, Papadoudis A, Kiagia M, Syrigos K.

J Pain Symptom Manage. 2018 May;55(5):1364-1381.e5. doi: 10.1016/j.jpainsymman.2017.12.491. Epub 2018 Jan 6.

PMID:
29309818
35.

Lung Metastasis From Fibrosarcomatous Dermatofibrosarcoma Protuberans of the Vulva: A Rare Case Report.

Vathiotis IA, Psichogiou E, Syrigos KN, Kotteas EA.

J Low Genit Tract Dis. 2018 Jan;22(1):85-87. doi: 10.1097/LGT.0000000000000360. No abstract available.

PMID:
29271862
36.

Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer.

Villarroel-Espindola F, Yu X, Datar I, Mani N, Sanmamed M, Velcheti V, Syrigos K, Toki M, Zhao H, Chen L, Herbst RS, Schalper KA.

Clin Cancer Res. 2018 Apr 1;24(7):1562-1573. doi: 10.1158/1078-0432.CCR-17-2542. Epub 2017 Dec 4.

37.

Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.

Paz-Ares LG, Pérol M, Ciuleanu TE, Kowalyszyn RD, Reck M, Lewanski CR, Syrigos K, Arrieta O, Prabhash K, Park K, Pikiel J, Göksel T, Lee P, Zimmermann A, Carter GC, Alexandris E, Garon EB.

Lung Cancer. 2017 Oct;112:126-133. doi: 10.1016/j.lungcan.2017.05.021. Epub 2017 Jun 3.

PMID:
29191585
38.

Anti-PD1/PDL1 induced psoriasis.

Voudouri D, Nikolaou V, Laschos K, Charpidou A, Soupos N, Triantafyllopoulou I, Panoutsopoulou I, Aravantinos G, Syrigos K, Stratigos A.

Curr Probl Cancer. 2017 Nov - Dec;41(6):407-412. doi: 10.1016/j.currproblcancer.2017.10.003. Epub 2017 Oct 18.

PMID:
29096940
39.

The Role of Tinzaparin in Oncology.

Dimakakos EP, Vathiotis I, Syrigos K.

Clin Appl Thromb Hemost. 2018 Jul;24(5):697-707. doi: 10.1177/1076029617729215. Epub 2017 Oct 31. Review.

40.

New data for venous thromboembolism in patients with small cell lung cancer: A review.

Dimakakos E, Livanios K, Gkiozos I, Charpidou A, Ntalakou E, Kainis L, Syrigos K.

Phlebology. 2018 Sep;33(8):517-522. doi: 10.1177/0268355517737670. Epub 2017 Oct 23. Review.

PMID:
29059023
41.

Management of Progressive Pulmonary Nodules Found during and outside of CT Lung Cancer Screening Studies.

Meyer M, Vliegenthart R, Henzler T, Buergy D, Giordano FA, Kostrzewa M, Rathmann N, Brustugun OT, Crino L, Dingemans AC, Dusmet M, Fennell D, Grunenwald D, Huber RM, Moniuszko M, Mornex F, Papotti M, Pilz L, Senan S, Syrigos K, Pérol M, Gray JE, Schabel C, van Meerbeeck JP, van Zandwijk N, Zhou CC, Manegold C, Voigt W, Roessner ED.

J Thorac Oncol. 2017 Dec;12(12):1755-1765. doi: 10.1016/j.jtho.2017.09.1956. Epub 2017 Sep 27. Review.

42.

Thermal ablation may improve outcomes in patients with colorectal liver metastasis: a case-control study.

Poulou LS, Thanos L, Ziakas PD, Merikas E, Achimastos A, Gennatas C, Syrigos KN.

J BUON. 2017 May-Jun;22(3):673-678.

43.

Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG).

Christodoulou C, Kalogera-Fountzila A, Karavasilis V, Kouvatseas G, Papandreou CN, Samantas E, Varaki K, Papadopoulos G, Bobos M, Rallis G, Razis E, Goudopoulou A, Kalogeras KT, Syrigos KN, Fountzilas G.

J Neurooncol. 2017 Sep;134(2):443-451. doi: 10.1007/s11060-017-2548-z. Epub 2017 Jul 7.

PMID:
28687923
44.

Chromosome 7 Multiplication in EGFR-positive Lung Carcinomas Based on Tissue Microarray Analysis.

Tsiambas E, Mastronikolis NS, Lefas AY, Georgiannos SN, Ragos V, Fotiades PP, Tsoukalas N, Kavantzas N, Karameris A, Peschos D, Patsouris E, Syrigos K.

In Vivo. 2017 Jul-Aug;31(4):641-648.

45.

Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.

Gadgeel S, Goss G, Soria JC, Felip E, Georgoulias V, Lu S, Cobo M, Syrigos K, Lee KH, Göker E, Guclu SZ, Isla D, Morabito A, Dupuis N, Bühnemann C, Krämer N, Solca F, Ehrnrooth E, Ardizzoni A.

Lung Cancer. 2017 Jul;109:101-108. doi: 10.1016/j.lungcan.2017.05.010. Epub 2017 May 11.

46.

Optimizing diet and nutrition for cancer survivors: A review.

Mourouti N, Panagiotakos DB, Kotteas EA, Syrigos KN.

Maturitas. 2017 Nov;105:33-36. doi: 10.1016/j.maturitas.2017.05.012. Epub 2017 May 19. Review.

PMID:
28545906
47.

B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.

Altan M, Pelekanou V, Schalper KA, Toki M, Gaule P, Syrigos K, Herbst RS, Rimm DL.

Clin Cancer Res. 2017 Sep 1;23(17):5202-5209. doi: 10.1158/1078-0432.CCR-16-3107. Epub 2017 May 24.

48.

Therapeutic Challenges in Neuroendocrine Tumors.

Legakis I, Saif MW, Syrigos K.

Anticancer Agents Med Chem. 2017;17(7):902-919. doi: 10.2174/1871520617666170213113401. Review.

PMID:
28270063
49.

Proof of the quantitative potential of immunofluorescence by mass spectrometry.

Toki MI, Cecchi F, Hembrough T, Syrigos KN, Rimm DL.

Lab Invest. 2017 Mar;97(3):329-334. doi: 10.1038/labinvest.2016.148. Epub 2017 Jan 16.

50.

The use of novel oral anticoagulants in cancer patients with venous thromboembolism.

Karakatsanis SJ, Roumpi A, Syrigos KN.

Semin Oncol. 2016 Dec;43(6):655-665. doi: 10.1053/j.seminoncol.2016.11.009. Epub 2016 Nov 18. Review.

PMID:
28061983

Supplemental Content

Loading ...
Support Center